7RPV
Crystal structure of affinity-enhancing and catalytically inactive ACE2 in complex with SARS-CoV-2 RBD
7RPV の概要
エントリーDOI | 10.2210/pdb7rpv/pdb |
分子名称 | Processed angiotensin-converting enzyme 2, Spike protein S1, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total) |
機能のキーワード | sars-cov-2, receptor binding domain, engineered human ace2, enhanced affinity, catalytic-null, zinc binding site, hydrolase-viral protein complex, hydrolase/viral protein |
由来する生物種 | Homo sapiens (Human) 詳細 |
タンパク質・核酸の鎖数 | 8 |
化学式量合計 | 380059.28 |
構造登録者 | |
主引用文献 | Chen, Y.,Sun, L.,Ullah, I.,Beaudoin-Bussieres, G.,Anand, S.P.,Hederman, A.P.,Tolbert, W.D.,Sherburn, R.,Nguyen, D.N.,Marchitto, L.,Ding, S.,Wu, D.,Luo, Y.,Gottumukkala, S.,Moran, S.,Kumar, P.,Piszczek, G.,Mothes, W.,Ackerman, M.E.,Finzi, A.,Uchil, P.D.,Gonzalez, F.J.,Pazgier, M. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. Biorxiv, 2021 Cited by PubMed Abstract: Soluble Angiotensin-Converting Enzyme 2 (ACE2) constitutes an attractive antiviral capable of targeting a wide range of coronaviruses utilizing ACE2 as their receptor. Here, using structure-guided approaches, we developed divalent ACE2 molecules by grafting the extracellular ACE2-domain onto a human IgG1 or IgG3 (ACE2-Fc). These ACE2-Fcs harbor structurally validated mutations that enhance spike (S) binding and remove angiotensin enzymatic activity. The lead variant bound tightly to S, mediated neutralization of SARS-CoV-2 variants of concern (VOCs) with sub-nanomolar IC and was capable of robust Fc-effector functions, including antibody-dependent-cellular cytotoxicity, phagocytosis and complement deposition. When tested in a stringent K18-hACE2 mouse model, it delayed death or effectively resolved lethal SARS-CoV-2 infection in a prophylactic or therapeutic setting utilizing the combined effect of neutralization and Fc-effector functions. These data confirm the utility of ACE2-Fcs as valuable agents in preventing and eliminating SARS-CoV-2 infection and demonstrate that ACE2-Fc therapeutic activity require Fc-effector functions. PubMed: 34845451DOI: 10.1101/2021.11.24.469776 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (3.54 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード